Mural Oncology’s Post

Ten years after the groundbreaking FDA approval of checkpoint inhibitors, immuno-oncology (IO) is on the cusp of a new era. In BioSpace, Mural CEO Caroline J Loew, PhD reflects on the challenges, advances, and promise of ‘IO 2.0’—a wave driven by nimble biotech companies like ours, bringing innovative therapies beyond PD-1 inhibitors aiming to transform cancer care. Read on to see why we’re excited about this next chapter in IO: https://lnkd.in/gXan3Nmb

  • No alternative text description for this image
Tony Fischetti

President & COO at Premier Pharma Executive Talent Sourcing, LLC

1mo

Hi Caroline Best of luck with your continued success. Please keep me in mind when you need to hire top talent for your team

Like
Reply

To view or add a comment, sign in

Explore topics